Icatibant

Details

Files

Generic Name:

Icatibant

Project Status:

Complete

Therapeutic Area:

Hereditary angioedema

Manufacturer:

Shire Human Genetic Therapies (Canada) Inc.

Call for patient/clinician input open:

June 25, 2014

Brand Name:

Firazyr

Project Line:

Reimbursement Review

Project Number:

SR0375-000

Call for patient/clinician input closed:

July 23, 2014

NOC Status at Filing:

Pre NOC

Performance Metric:

N/A — Predated performance metrics

Submission Type:

Initial

Indications:

Angioedema, hereditary

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

December 19, 2014

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Clinical Report View PDF

Pharmcoeconomic Report View PDF

Last Updated : March 4, 2014